FRM
KROS icon

Fox Run Management’s Keros Therapeutics KROS Stock Holding History

Fox Run Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$243K Sell
22,790
-2,890
-11% -$44.6K 0.04% 693
2025
Q4 		$523K Buy
+25,680
New +$451K 0.08% 481
2025
Q3 		– Sell
-12,354
Closed -$165K – 1087
2025
Q2 		$165K Sell
12,354
-6,635
-35% -$89.6K 0.03% 771
2025
Q1 		$193K Sell
18,989
-3,224
-15% -$37.4K 0.03% 803
2024
Q4 		$352K Buy
22,213
+16,069
+262% +$835K 0.06% 568
2024
Q3 		$357K Buy
+6,144
New +$303K 0.08% 485

Other funds holding KROS

BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $1.6B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $70.4B AUM 20.22% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return